Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Ref Type | Journal Article | ||||||||||||
| PMID | (41110693) | ||||||||||||
| Authors | Peters S, Camidge R, Dziadziuszko R, Gadgeel S, Shaw AT, Kim DW, Pérol M, Rosell DR, Cheema P, Lim DW, Lin JJ, Pavlakis N, Ahn JS, Zhang L, Henschel V, Higgerson AA, McNally V, Rooney I, Scalori A, Smoljanovic V, Mok T | ||||||||||||
| Title | Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: Final overall survival analysis of the Phase III ALEX study. | ||||||||||||
|
|||||||||||||
| URL | |||||||||||||
| Abstract Text | ALEX, a global, randomized, phase III trial evaluated alectinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer (NSCLC). This final analysis provides mature overall survival (OS), duration of response (DOR) and long-term safety data.Treatment-naïve patients with stage III/IV ALK-positive NSCLC were randomly assigned to receive alectinib (600 mg twice daily [BID]) or crizotinib (250 mg BID) until disease progression, unacceptable toxicity, withdrawal, or death. Primary endpoint was investigator-assessed progression-free survival (previously reported). Key secondary endpoints included OS, DOR and safety.A total of 303 patients (alectinib, n=152; crizotinib, n=151) were enrolled. At the updated data cutoff (28 April 2025), after a median follow-up of 53.5 (alectinib) and 23.3 (crizotinib) months, median OS was 81.1 (95% CI 62.3-not estimable) versus 54.2 (95% CI 34.6-75.6) months, respectively (hazard ratio [HR] 0.78; 95% CI 0.56-1.08). Improvement in median OS was observed with alectinib in patients with and without CNS metastases at baseline (with CNS metastases: 63.4 [n=59] versus 30.9 [n=53] months with alectinib versus crizotinib, respectively [HR 0.68; 95% CI 0.40-1.15]; without CNS metastases: 94.0 [n=93] versus 69.8 [n=98] months [HR 0.87; 95% CI 0.58-1.32]). Median DOR in confirmed responders was longer with alectinib (42.3 months, 95% CI 31.3-51.3) versus crizotinib (11.1 months, 95% CI 7.9-13.0 [HR 0.41; 95% CI 0.30-0.56]). Long-term safety (median duration of alectinib treatment, 28.1 months) remained consistent with earlier reports, with no new or unexpected safety concerns identified.These final OS data show the sustained long-term systemic and intracranial efficacy of alectinib in the first-line treatment of ALK-positive NSCLC and confirm alectinib as a standard of care in this setting. | ||||||||||||
| Molecular Profile | Treatment Approach |
|---|
| Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
|---|
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|
| Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
|---|
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ALK rearrange | lung non-small cell carcinoma | sensitive | Alectinib | Phase III | Actionable | In a Phase III trial (ALEX), treatment with Alecensa (alectinib) in treatment-naive non-small cell lung cancer patients harboring ALK rearrangements improved median overall survival in patients with CNS metastases (63.4 vs 30.9 months, HR=0.68) and without (94.0 vs 69.8 months, HR=0.87) and improved median duration of response (42.3 vs 11.1 months, HR=0.41) compared to treatment with Xalkori (crizotinib) (PMID: 41110693; NCT02075840). | 41110693 |